A congenital deficiency of the coagulation Factor XIII A subunit (F XIII A) is a rare autosomal recessive disorder that is characterized by a life-long bleeding tendency complicated by a difficulty in healing. Thus far, no molecular genetic analysis of this disorder has been reported. In this study, we demonstrate the molecular abnormalities in a family with this disorder. We performed Northern blot analysis of peripheral blood monocytes obtained from the propositus and found a 4-kb single band of F XIII A mRNA whose size was identical with that of normal subjects. Exons II-XV, which encode all the amino acids, were individually amplified by a polymerase chain reaction (PCR). All PCR products from the propositus had lengths indistinguishable from those of the wild type on agarose gel, suggesting that this defect results from either a point mutation or a short deletion/insertion. The sequencing of F XIII A cDNA from the propositus revealed a deletion of the dinucleotide AG within the AGAG repeat at the position of 210 to 213. Concerning the genomic sequence, a deletion of dinucleotide AG was also demonstrated in the intron B-exon III boundary. This deletion appeared to cause a frameshift mutation making a new stop codon shortly thereafter, and leading to a deficiency of plasma F XIII A. The heterozygosity of the F XIII A deficiency in the patient's offspring was documented by the nucleotide sequences of their exon III. (J. Clin. Invest. 1992. 90:315-319.)
Introduction
Coagulation Factor XIII (F XIII)' is a transglutaminase that crosslinks a fibrin monomer into a stable clot in the final stages of blood coagulation (1) . In addition to that fibrin monomer, substance such as von Willebrand factor, a2-plasmin inhibitor, 1 . Abbreviations used in this paper: F XIII, coagulation Factor XIII; F XIII A, coagulation Factor XIII A subunit; PCR, polymerase chain reaction.
thrombospondin, and fibronectin are also crosslinked into a fibrin clot by this enzyme. Such crosslinking leads to an increased resistance to digestion by plasmin (2, 3) , as well as to an increased mechanical strength ofthe clot (4, 5) . Factor XIII circulates in the plasma as a tetramer (A2B2, mol wt 320,000) consisting of two A subunits (mol wt 75,000) and two B subunits (mol wt 80,000) (6) (7) (8) . The A subunit (F XIII A) is the catalytically active subunit, while the B subunit (F XIII B) may primarily play a role ofa carrier protein protecting the circulating A subunit (6) (7) (8) .
The A and B subunits are separately synthesized by different cells and form a tetramer in the plasma. The A subunit has been reported to be synthesized mainly by platelets/megakaryocytes, monocytes/macrophages, and the placenta, and to be localized in the cytoplasm of those cells as dimers (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) .
The hereditary deficiency of F XIII is a rare autosomal recessive disorder, and this frequency has been reported to be one in 2 x 106 (18) . This disorder was first reported in 1960 by Duckert et al. (19) . Since then, about 160 patients with a F XIII deficiency have been reported, characterized by life-threatening bleeding, difficulty in healing, and a high risk of miscarriage (18, 19) . Although a complete absence of the A subunit was demonstrated in most cases, a few instances ofa deficiency of the B subunit have also been reported (20, 21) .
The primary structure of human F XIII A has been elucidated from the amino acid sequence (22, 23) and cDNA sequence obtained from the human placental library (24) . F XIII A cDNA consists of 3,902 bases, which include 2,196 bases of coding region for 732 amino acids, 81 bases of 5', and 1,625 bases of 3' nontranslated regions (22) (23) (24) . The F XIII A gene is mapped at chromosome 6p24-p25 (25, 26 (29) .
Isolation ofgenomic DNA and RNA. 30 ml of peripheral blood was obtained from the patient and his family members, using sodium heparin as an anticoagulant. Genomic DNA from leukocytes was isolated according to the standard method (30) . DNA was dissolved in 1 ml of 10 mmol/liter of Tris-HCl, 1 mmol/l EDTA, pH 8 (TE buffer) and stored at 4°C until used. The total RNA was isolated from the PBMC by guanidinium thiocyanate extraction (31 ) , and were then purified by ultracentrifugation on a cesium chloride gradient. The RNA was dissolved in H20 and stored at -70°C until used.
Northern and Southern blot analysis. 10 gg of total RNA was separated on a 1% formaldehyde agarose gel and then was transferred to a Nytran Nylon membrane. After endonuclease (HindIII, PvuII, and BamHI) digestion, 10 Ag of leukocyte DNA was electrophoresed on a 0.8% agarose gel and was transferred. These membranes were hybridized with the F XIII A cDNA probe radiolabeled with [a-32PldCTP using the random primer method. (Table I) . Each cycle consisted of 1 min at 940C, 2 min at 550C, and 1 min at 720C. The final extension was carried out for 7 min at 72°C. The amplified PCR products were electrophoresed on a 2% agarose gel and were stained with ethidium bromide.
Synthesis ofcDNA and PCR amplification ofcDNA (reverse transcriptase [RT]-PCR). First-strand cDNA was generated from 1 jgg of total RNA using oligo (dT) primers and reverse transcriptase. Four pairs of PCR primers were designed according to the normal cDNA sequence (Table II) . The sequences ofthe primers were partially modified to make a restriction enzyme site near their 5' ends. The nucleotide numbers 19 to 2352 of cDNA, which cover the entire amino acid coding region, were divided into four overlapping fragments named A, B, C, and D, which included nucleotides 19-766, 596-1275, 1158-1695, and 1630-2352, respectively (Fig. 2) . Each fragment was amplified under the same conditions as described above. To confirm that these products had the predicted sequence, they were digested by restriction endonucleases that recognized the known sites as shown in Fig. 2 , and, in addition, they were electrophoresed on a 2% agarose gel and stained with ethidium bromide.
Subcloning and DNA sequence ofPCR products. The PCR products were subcloned using pUC19 and competent cells derived from E. coli strain DH5a. Plasmids were prepared from the transformed E. coli by the method of Maniatis (33) . Following the alkaline degeneration of plasmids, inserts were sequenced from both sides with the dideoxynucleotide chain-termination method (34) . The reaction mixtures for sequencing were electrophoresed at 45 W on a 5% long ranger gel. The gel was then dried and exposed on Fuji RX Film for 24 h at room temperature. 
Results
The propositus showed a complete absence of both functional and immunodetectable F XIII A in the plasma. The antigen level of F XIII B was reduced to 29% ofthe normal concentration. Therefore, the propositus was considered to have a homozygous deficiency of F XIII A. As shown in Fig. 1 , it was suggested that one sibling (IV-7) had a homozygous deficiency. His mother (III-9), another sibling (IV-6), and three offspring (V-l, 2, 3) were all considered to be heterozygotes. With Northern blot analysis, a 4-kb single band ofF XIII A mRNA was detected in PBMC from the patient, identical in size to those from a normal PBMC and U 937 (monocytic leukemia cell line), as shown in Fig. 3 . With Southern blot analysis, no major deletion or rearrangement of the F XIII A gene was found (data not shown).
The PCR products individually amplified from 14 exons (Exon II to XV) ofthe propositus were indistinguishable from those predicted from a normal gene sequence on a agarose gel (data not shown) (27) .
Messenger RNA in PBMC from the propositus was amplified by the RT-PCR method. The lengths and restriction sites offour fragments (A, B, C, and D) were also almost identical to those predicted from normal individuals (data not shown) (27) . These observations suggest that either a point mutation or a minor deletion/insertion was responsible for the deficiency.
PCR products of fragments A, B, C, and D were subcloned into pUCl 9, and the plasmids from two to three independent clones containing each fragment were sequenced. As shown in Fig. 4 A, a two-base (A and G) deletion within the AGAG sequence at the nucleotide position of 210 to 213 was found in the PCR fragment A. We could not distinguish whether AG or GA was removed from the AGAG repeat, which is the boundary of exon II and III. In either case, this deletion caused a frameshift mutation and made a stop codon (TAA) at six bases downstream from the deletion site (Fig. 4 C) . In order to confirm this result, PCR products from exon III, including the adjacent introns, were subcloned into pUC19 and the plasmids from six independent clones were sequenced. In the sequence of the wild type, ---CATAGAGTTT---is known to be at the boundary of intron B and exon III (27) . However, ---CATAGTTT---was found at this site in all six clones from the propositus, indicating a two-base (A and G) deletion within the AGAG repeat (Fig. 4 B and C) . As with cDNA sequencing, it could not be determined which two nucleotides had been deleted, while three possibilities existed: the first AG, the central GA, and the last AG deletion within the AGAG repeat. In either case, the remaining AG becomes a splice acceptor site of intron B, leading to a deletion of AG at the 212 and 213 position in the mRNA from the propositus. Analysis of the DNA sequences of exon III from two ofthe 1 2 3 4 5 4.0 kbs *-e 4. kb patient's offspring (V-1 and 2) revealed the heterozygosity of the wild type and mutant alleles identical with that of the patient (Fig. 5 ).
Discussion
Hemostatic analysis of the propositus showed a typical deficiency of F XIII A. The family study revealed the presence ofa congenital homozygous F XIII A deficiency in the propositus. The level of the plasma B subunit in this case was reduced to 29% of the normal concentration, as previously mentioned in (35) (36) (37) (38) . In these cases, either a point mutation or a short deletion occurred in the region including the obligatory AG as a 3' splice acceptor consensus in intron, leading to an elongation ofthe intron as well as exon skipping. Due to the incidental presence of the AGAG repeat at the intron B-exon III boundary of the F XIII A gene, a major deletion in mRNA was avoided in this case.
Previously, six sites of polymorphism were described in the levels of amino acid, cDNA and gene in F XIII A (22) (23) (24) 27 ). In our case, we found six sites, 77 Arg (CGC), 78 Arg (AGA), 88 Phe (TTC), 564 Pro (CCG), 650 Ile (ATT), and 651 Gln (CAG) . No other polymorphisms were newly identified in this study. This is the first report to characterize the genetic abnormality present in a case of a congenital F XIII A deficiency. As previously found with other genetic disorders, it is possible that the genetic abnormality in this disorder is not identical in all cases. Additional genetic analysis is required, and additional mutations will have to be further identified in this bleeding disorder. Such genetic analyses may ultimately be helpful in future gene therapy applications.
In conclusion, the F XIII A deficiency described in our patient was characterized by dinucleotide (AG) deletion at the 5' end of exon III.
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